According to the World Health Organization, NEN can be divided into well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC).
Despite their relatively low but increasing incidence, the global prevalence of NET (35 patients per 100,000) is higher than the combined prevalence of other more common gastrointestinal malignancies (esophageal, gastric, and pancreatic cancers), due to the chronic nature of NET.
The proposed research will focus on NET from the gastroenteropancreatic tract and lung as they make up 94% of all NEN and are clinically and biologically very distinct from NEC.
More information about neuroendocrine cancer can also be found on the website of INCA (International Neuroendocrine Cancer Alliance). INCA is the global voice for patients with neuroendocrine cancer and genetic neuroendocrine.
Why it matters
To date, surgery and/or locoregional therapy remains the cornerstone for curative treatment for non-metastasized NET, but recent data and real-world evidence report recurrence rates up to 15-50%.
Moreover, 40–50% of NET patients present with distant metastases at initial diagnosis. For these patients, systemic treatment options are used to delay tumor growth, but they do not offer a cure and have limited impact on long-term progression. Despite a 5-year survival rate of 57%, the current treatment options only manage to stall disease progression and patients ultimately succumb to their disease.
A remarkable proportion of all new treatment options in other solid tumors is represented by immune-driven strategies, which leverage the immune system's ability to recognize and destroy cancer cells. The current generation of immunotherapies, such as immune checkpoint inhibitors (ICI), however, have only limited efficacy in NET and novel strategies are therefore direly needed.
Addressing the problem
Given the impactful preclinical research currently shaping the immunotherapy field, with more advanced strategies that achieve durable antitumor responses and outperform conventional antineoplastic modalities even in tumors resistant to the established types of immune-driven strategies such as ICI, it is imperative to leverage this momentum to systematically adapt and optimize next-generation immune-driven strategies for NET.
Both Europe's Beating Cancer Plan (EBCP) and EU Cancer Mission highlight the opportunity of using the EU’s unique position to maximize translational research on rare cancers by enhancing horizontal collaboration and pooling scientific expertise, patient samples, clinical and research data.
For the first time in the NET field, we will leverage the EU’s unique collaborative framework to educate and empower a new generation of researchers specialized in NET biology by pooling scientific expertise, biological resources, and data.